Kymriah (Tisagenlecleucel)

Tisagenlecleucel is produced by collecting a patient’s own T cells, genetically engineering them with a viral vector to express a chimeric antigen receptor that recognises CD19 on B‑cell malignancies, expanding the modified cells, and reinfusing them. The CAR‑modified T cells bind CD19, become activated, proliferate, and destroy CD19‑positive cancer cells through cytotoxic mechanisms.

The dose of Kymriah is individualized. After leukapheresis, the manufacturing process determines the final cell dose, which the prescribing physician calculates based on the patient’s body weight and disease characteristics. The exact number of viable CAR‑T cells to be infused is therefore set by the treating clinician in accordance with approved labeling.

Safety of Kymriah in pregnancy and lactation has not been established. The product carries an unknown pregnancy category, and potential risks to the fetus or infant cannot be ruled out. Use is only considered when the anticipated benefit outweighs the possible risks, and a thorough discussion with a specialist is recommended.

To request Kymriah, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Kymriah (tisagenlecleucel) targets CD19 like other approved CAR‑T products such as axicabtagene ciloleucel, but differs in its manufacturing process, approved indications, and age range. Kymriah is authorized for pediatric and young adult ALL and for adult large B‑cell lymphoma, whereas some alternatives are limited to specific lymphoma subtypes or adult populations.

Kymriah must be stored at 2 °C to 8 °C in a validated refrigerator. The product should be kept in its original packaging, protected from light, and must never be frozen or shaken. Temperature logs are required during transport to maintain the cold‑chain integrity.

Kymriah is delivered as a single intravenous infusion of autologous T‑cell product after a conditioning chemotherapy regimen. The infusion is performed in a specialized center equipped for cellular therapies, with continuous monitoring for infusion reactions, cytokine release syndrome and neurotoxicity during and after the administration.

The most serious adverse events include cytokine release syndrome, which can be life‑threatening, and immune effector cell‑associated neurotoxicity syndrome (ICANS), which may cause severe neurological impairment. Additional critical risks are prolonged cytopenias, severe infections, and tumor lysis syndrome, all requiring vigilant monitoring and prompt intervention.

Patients with active uncontrolled infections, those who have received recent live vaccines, or individuals whose disease does not express CD19 should not be treated with Kymriah. Additionally, patients who are unable to undergo leukapheresis or who have contraindications to the required conditioning chemotherapy are generally excluded.